Deferiprone
| Evidence Level: L4 | Predicted Indications: 9 |
Table of Contents
Deferiprone: From Transfusional Iron Overload (Thalassemia) to Hepatic Porphyria
One-Sentence Summary
Deferiprone is an oral iron chelator whose established clinical role is managing transfusional iron overload in β-thalassemia. The TxGNN model predicts it may also be effective for Hepatic Porphyria, but this direction is currently supported only by 0 clinical trials and 2 indirect publications (an animal model and a case report in a different porphyria subtype).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Transfusional iron overload in β-thalassemia (established clinical use; not confirmed by a formal MOA record in this evidence pack) |
| Predicted New Indication | Hepatic porphyria |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a data gap in this evidence pack). Based on known information, deferiprone is an oral, bidentate iron chelator that forms 3:1 (chelator:Fe³⁺) complexes; its core clinical use is reducing iron overload in transfusion-dependent β-thalassemia, an indication corroborated within this evidence pack itself (see the rank-8 candidate below).
The link to hepatic porphyria rests on a shared mechanistic hypothesis: iron catalyses the oxidation of porphyrin precursors, a key toxic step in porphyria pathophysiology. Iron chelation has shown benefit in related but distinct models — a murine model of porphyria cutanea tarda (hepatic iron reduction reducing uroporphyrin accumulation) and a human case series of congenital erythropoietic porphyria (an erythropoietic, not hepatic, porphyria) showing reduced haemolysis and photosensitivity with iron chelation.
Neither publication studies hepatic porphyria directly, so the mechanistic rationale is plausible but extrapolated across disease subtypes and species. This is reflected in the L4 evidence level (mechanism/preclinical only) and the “Research Question” decision stage assigned by the scoring model.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32678895 | 2020 | Case Report/Case Series | Blood | Iron chelation reduced haemolytic anaemia and skin photosensitivity in congenital erythropoietic porphyria (an erythropoietic, not hepatic, porphyria) |
| 17854053 | 2007 | Animal Study | Hepatology (Baltimore, Md.) | In an Hfe⁻/⁻ murine model of porphyria cutanea tarda, oral iron chelation with deferiprone (L1) reduced hepatic uroporphyrin accumulation, comparably to iron-deficient diets |
UK Market Information
Deferiprone is currently not marketed in the UK, and no marketing authorisations are on record in this evidence pack.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: TFDA/MHRA-equivalent warning and contraindication data for this product is currently a blocking data gap (see Next Steps below) and must be resolved before any safety assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The hepatic porphyria hypothesis is supported only by mechanistic extrapolation from an animal model and a case series in a different (erythropoietic) porphyria subtype — no direct evidence exists in the hepatic porphyria population, and no clinical trials are registered. Combined with a blocking gap in formal safety/warning data, the evidence does not yet support progression beyond a research question.
To proceed, the following is needed:
- Official UK/MHRA SmPC warnings, contraindications and DDI data (currently a blocking data gap)
- Verified mechanism of action documentation from DrugBank
- Direct preclinical or clinical evidence in a hepatic porphyria population (current literature is in erythropoietic porphyria and a PCT mouse model only)
- Clarification of deferiprone’s UK regulatory status for its established indication (transfusional iron overload) as groundwork before considering repurposing
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.